{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"16.0"},{"groupId":"OG001","spread":"1.2","value":"15.3"},{"groupId":"OG002","spread":"2.9","value":"14.3"},{"groupId":"OG003","spread":"0.0","value":"16.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Baseline (pre-treatment)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.2","value":"7.3"},{"groupId":"OG001","spread":"5.3","value":"11.8"},{"groupId":"OG002","spread":"3.5","value":"12.7"},{"groupId":"OG003","spread":"4.9","value":"5.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Pre-cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.1","value":"6.5"},{"groupId":"OG001","spread":"4.0","value":"11.7"},{"groupId":"OG002","spread":"5.6","value":"11.0"},{"groupId":"OG003","spread":"6.3","value":"8.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Post cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.2","value":"5.0"},{"groupId":"OG002","spread":"5.7","value":"11.3"},{"groupId":"OG003","spread":"2.3","value":"10.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Six months post chemo"},{"categories":[{"measurements":[{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG000","spread":"NA","value":"16.0"},{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG001","spread":"NA","value":"10.0"},{"groupId":"OG002","spread":"4.9","value":"9.5"},{"groupId":"OG003","spread":"3.8","value":"11.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"End of bevacizumab (BEV)"},{"categories":[{"measurements":[{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG000","spread":"NA","value":"10.0"},{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG001","spread":"NA","value":"10.0"},{"groupId":"OG002","spread":"4.2","value":"9.0"},{"groupId":"OG003","spread":"9.9","value":"7.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Six months after BEV"},{"categories":[{"measurements":[{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG000","spread":"NA","value":"8.0"},{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG001","spread":"NA","value":"14.0"},{"groupId":"OG002","spread":"4.9","value":"5.5"},{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG003","spread":"NA","value":"16.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"2 years after BEV"},{"categories":[{"measurements":[{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG000","spread":"NA","value":"14.0"},{"groupId":"OG002","spread":"4.9","value":"9.5"},{"comment":"Standard deviation is not presented if only one valid assessment was received.","groupId":"OG003","spread":"NA","value":"16.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"3 years after BEV"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"6.4","value":"6.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"4 years after BEV"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"3.5","value":"7.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"5 years after BEV"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Patient reported neurotoxicity symptoms as measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggests less neurotoxicity.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm I (Carboplatin and Paclitaxel)"},{"description":"Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCapecitabine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nOxaliplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Arm II (Oxaliplatin and Capecitabine)"},{"description":"Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG002","title":"Arm III (Carboplatin, Paclitaxel, Bevacizumab)"},{"description":"Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.\n\nBevacizumab: Given IV\n\nCapecitabine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nOxaliplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG003","title":"Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)"}],"paramType":"MEAN","populationDescription":"Patients who provided a valid FACT/GOG-Ntx subscale assessment. Data were not collected at certain time points for certain arms.","reportingStatus":"POSTED","timeFrame":"baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5","title":"Patient Reported Neurotoxicity","type":"SECONDARY","unitOfMeasure":"units on a scale."}